ArticleScientific reports2026
Interactive dynamic modulation of antidepressant treatment response by serum interleukin-1β and Neuroticism at 12 weeks.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examined how serum interleukin-1 beta (sIL-1β) interacts with the Big Five personality trait of Neuroticism to influence 12-week antidepressant treatment outcomes in patients with depressive disorders. Baseline measurements of sIL-1β and Neuroticism were obtained from 1086 participants enrolled in a naturalistic, stepwise antidepressant treatment program. Remission was defined as a Hamilton depression rating scale score of 7 or below after 12 weeks of treatment. Using logistic regression models that accounted for sociodemographic and clinical variables, we assessed the independent and interactive effects of these factors on treatment response. Elevated sIL-1β levels were significantly associated with non-remission in participants with high Neuroticism, whereas this relationship was not evident among those with lower Neuroticism levels. Notably, the interaction between sIL-1β and Neuroticism was a significant predictor of remission status, even after adjusting for confounders. Our findings reveal that the dynamic modulation of antidepressant response through the interaction of sIL-1β and Neuroticism could inform more personalized treatment strategies, enhancing clinical outcomes for patients with depression. Future research should continue to explore these biomarker-psychological trait interactions to fully understand their role in treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.